IntelGenx Technologies Inc. is a specialty pharmaceutical company headquartered in Montreal, Canada, that focuses on the development and commercialization of novel drug delivery systems. Established to address limitations of traditional oral and injectable formulations, the company’s technology platforms aim to improve patient compliance, enhance bioavailability and provide controlled release profiles for a variety of therapeutic agents.
The core of IntelGenx’s offering lies in its proprietary film-based delivery technologies, including RapidFilm and MucoFilm, which are thin polymer films designed for oral mucosal administration. These films can dissolve quickly or be formulated for sustained release, enabling delivery of small molecules, peptides and other active pharmaceutical ingredients without the need for water or swallowing. In addition, the company is advancing its ProNeura long-acting drug delivery system, an implantable rod designed for sustained release over periods of months to years, with potential applications in chronic disease and hormone therapies.
IntelGenx collaborates with pharmaceutical partners around the world to in-license development candidates and out-license its delivery platforms for late-stage clinical or commercial programs. With strategic alliances spanning North America, Europe and other regions, the company seeks to leverage its manufacturing facility in Cowansville, Québec, to support both clinical supply and commercial production. Led by a management team with extensive experience in formulation science and pharmaceutical product development, IntelGenx continues to advance a pipeline of programs aimed at addressing unmet medical needs and improving patient outcomes.
AI Generated. May Contain Errors.
